Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34098
Title: The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes: a systematic review of randomised controlled trials.
Austin Authors: Chan, Miin;Larsen, Nadja;Baxter, Helen ;Jespersen, Lene;Ekinci, Elif I ;Howell, Kate
Affiliation: School of Agriculture, Food and Ecosystem Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.
Austin Health Sciences Library
Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.
Endocrinology
School of Agriculture, Food and Ecosystem Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Issue Date: 26-Oct-2023
Date: 2023
Publication information: Nutrition Research Reviews 2023-10-26
Abstract: Our systematic review assessed the impact of botanical fermented food (BFF) consumption on glucose, lipid, anthropometric, inflammatory and gut microbiota parameters, in adults with metabolic syndrome (MetS), MetS components or type 2 diabetes mellitus (T2DM). Embase, MEDLINE, Cochrane CENTRAL and Google Scholar were searched with no language limits, from inception to August 31, 2022, for eligible randomised controlled trials (RCTs). Two independent reviewers screened 6873 abstracts and extracted relevant data. Risk of bias (ROB) was assessed using the Cochrane Collaboration's ROB2 tool. The final review included 26 RCTs, with 31 reports published between 2001 and 2022. Significant (p<0.05) within-group and between-group changes in cardiometabolic outcome means were reported in 23 and 19 studies, respectively. Gut microbiota composition was assessed in four studies, with two finding significant between-group differences. No significant difference between groups of any measured outcomes was observed in five studies. There were 14 studies at low ROB; ten were of some concern; and two were at high ROB. In 73% of included studies, BFF consumption by participants with obesity, MetS or T2DM led to significant between-group improvements in discrete cardiometabolic outcomes, including fasting blood glucose, lipid profile, blood pressure, waist circumference, body fat percentage, and C-reactive protein. BFF consumption increased the abundance of beneficial gut bacteria, such as Bifidobacterium and LAB, whilst reducing potential pathogens like Bacteroides. To determine the clinical significance of BFFs as therapeutic dietary adjuncts, their safety, tolerability and affordability must be balanced with the limited power and magnitude of these preliminary findings.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34098
DOI: 10.1017/S0954422423000252
ORCID: 0000-0001-6579-8584
0000-0001-6498-0472
Journal: Nutrition Research Reviews
Start page: 1
End page: 46
PubMed URL: 37881833
ISSN: 1475-2700
Type: Journal Article
Subjects: Botanical fermented foods
diabetes
glycaemic control
gut microbiota
inflammatory markers
metabolic syndrome
obesity
plant based
systematic review
Appears in Collections:Journal articles

Show full item record

Page view(s)

52
checked on Oct 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.